Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial
Background Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-indu...
Uložené v:
| Vydané v: | Current controlled trials in cardiovascular medicine Ročník 23; číslo 1; s. 928 - 13 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
08.11.2022
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1745-6215, 1745-6215 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily).
Methods
This is a randomized controlled, phase III, multicenter, 2 × 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age ≥15 years with TBM defined as “definite,” “probable,” or “possible” using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40.
Discussion
The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries.
Trial registration
ClinicalTrials.gov NCT04145258. Registered on October 30, 2019. |
|---|---|
| AbstractList | BACKGROUND: Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily). METHODS: This is a randomized controlled, phase III, multicenter, 2 × 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age ≥15 years with TBM defined as "definite," "probable," or "possible" using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40. DISCUSSION: The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries. TRIAL REGISTRATION: ClinicalTrials.gov NCT04145258. Registered on October 30, 2019. Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily).BACKGROUNDTuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily).This is a randomized controlled, phase III, multicenter, 2 × 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age ≥15 years with TBM defined as "definite," "probable," or "possible" using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40.METHODSThis is a randomized controlled, phase III, multicenter, 2 × 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age ≥15 years with TBM defined as "definite," "probable," or "possible" using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40.The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries.DISCUSSIONThe INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries.ClinicalTrials.gov NCT04145258. Registered on October 30, 2019.TRIAL REGISTRATIONClinicalTrials.gov NCT04145258. Registered on October 30, 2019. Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily). This is a randomized controlled, phase III, multicenter, 2 × 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age ≥15 years with TBM defined as "definite," "probable," or "possible" using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40. The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries. ClinicalTrials.gov NCT04145258. Registered on October 30, 2019. Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily). This is a randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age [greater than or equal to]15 years with TBM defined as "definite," "probable," or "possible" using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40. The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries. Background Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily). Methods This is a randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age [greater than or equal to]15 years with TBM defined as "definite," "probable," or "possible" using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40. Discussion The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries. Trial registration ClinicalTrials.gov NCT04145258. Registered on October 30, 2019. Keywords: Randomized controlled trial, Tuberculous meningitis, Aspirin, Linezolid, HIV, High-dose rifampicin Background Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily). Methods This is a randomized controlled, phase III, multicenter, 2 × 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age ≥15 years with TBM defined as “definite,” “probable,” or “possible” using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40. Discussion The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries. Trial registration ClinicalTrials.gov NCT04145258. Registered on October 30, 2019. BackgroundTuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily).MethodsThis is a randomized controlled, phase III, multicenter, 2 × 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age ≥15 years with TBM defined as “definite,” “probable,” or “possible” using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40.DiscussionThe INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries.Trial registrationClinicalTrials.gov NCT04145258. Registered on October 30, 2019. Abstract Background Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily). Methods This is a randomized controlled, phase III, multicenter, 2 × 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age ≥15 years with TBM defined as “definite,” “probable,” or “possible” using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40. Discussion The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries. Trial registration ClinicalTrials.gov NCT04145258. Registered on October 30, 2019. |
| ArticleNumber | 928 |
| Audience | Academic |
| Author | Ambrosioni, Juan Wasserman, Sean Calvo-Cortes, Maria-Camilla Anglaret, Xavier Maitre, Thomas Wilkinson, Robert Miró, José M. Bonnet, Maryline Meintjes, Graeme Raberahona, Mihaja Debeaudrap, Pierre Bonnet, Fabrice Rakotoarivelo, Rivonirina Andry Nogbou, Frédéric Ello Chazallon, Corine Rakotosamimanana, Niaina Muzoora, Conrad Davis, Angharad Calmy, Alexandra Eholié, Serge Machault, Vanessa |
| Author_xml | – sequence: 1 givenname: Thomas surname: Maitre fullname: Maitre, Thomas organization: Sorbonne Université, INSERM U1135, Cimi-Paris, Department of Pneumology and Thoracic oncology, Reference Centre for Rare Lung Diseases, APHP Tenon Hospital – sequence: 2 givenname: Maryline surname: Bonnet fullname: Bonnet, Maryline organization: Université Montpellier, IRD, INSERM, TransVIHMI – sequence: 3 givenname: Alexandra surname: Calmy fullname: Calmy, Alexandra organization: Division of Infectious Diseases, HIV-AIDS Unit, Geneva University Hospitals – sequence: 4 givenname: Mihaja surname: Raberahona fullname: Raberahona, Mihaja organization: Centre d’Infectiologie Charles Mérieux (CICM), University of Antananarivo, Infectious Diseases Department, University Hospital Joseph Raseta Befelatanana – sequence: 5 givenname: Rivonirina Andry surname: Rakotoarivelo fullname: Rakotoarivelo, Rivonirina Andry organization: Centre d’Infectiologie Charles Mérieux (CICM), Infectious Diseases Department, University Hospital Tambohobe, Faculty of Medicine, University of Fianarantsoa – sequence: 6 givenname: Niaina surname: Rakotosamimanana fullname: Rakotosamimanana, Niaina organization: Mycobacteria Unit, Institut Pasteur de Madagascar – sequence: 7 givenname: Juan surname: Ambrosioni fullname: Ambrosioni, Juan organization: HIV Unit, Infectious Diseases Service, Hospital Clínic-IDIBAPS, University of Barcelona, CIBERINFEC. Instituto de Salud Carlos III – sequence: 8 givenname: José M. surname: Miró fullname: Miró, José M. organization: HIV Unit, Infectious Diseases Service, Hospital Clínic-IDIBAPS, University of Barcelona, CIBERINFEC. Instituto de Salud Carlos III – sequence: 9 givenname: Pierre surname: Debeaudrap fullname: Debeaudrap, Pierre organization: CEPED, Institut de Recherche pour le Développement, Université Paris Descartes, INSERM 1244 – sequence: 10 givenname: Conrad surname: Muzoora fullname: Muzoora, Conrad organization: Department of Internal Medicine, Mbarara University of Science and Technology, Médecins Sans Frontières (MSF) Epicentre – sequence: 11 givenname: Angharad surname: Davis fullname: Davis, Angharad organization: The Francis Crick Institute, Faculty of Life Sciences, University College London, Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town – sequence: 12 givenname: Graeme surname: Meintjes fullname: Meintjes, Graeme organization: Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Department of Medicine, University of Cape Town – sequence: 13 givenname: Sean surname: Wasserman fullname: Wasserman, Sean organization: Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Division of Infectious Diseases and HIV Medicine, Groote Schuur Hospital, University of Cape Town – sequence: 14 givenname: Robert surname: Wilkinson fullname: Wilkinson, Robert organization: The Francis Crick Institute, Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Department of Infectious Diseases, Imperial College – sequence: 15 givenname: Serge surname: Eholié fullname: Eholié, Serge organization: Centre Hospitalier Universitaire (CHU) Treichville – sequence: 16 givenname: Frédéric Ello surname: Nogbou fullname: Nogbou, Frédéric Ello organization: Programme ANRS Coopération Côte d’Ivoire (PAC-CI) – sequence: 17 givenname: Maria-Camilla surname: Calvo-Cortes fullname: Calvo-Cortes, Maria-Camilla organization: Inserm – ANRS|MIE (Emerging Infectious Diseases) – sequence: 18 givenname: Corine surname: Chazallon fullname: Chazallon, Corine organization: University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre – sequence: 19 givenname: Vanessa surname: Machault fullname: Machault, Vanessa organization: University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre – sequence: 20 givenname: Xavier surname: Anglaret fullname: Anglaret, Xavier organization: University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre – sequence: 21 givenname: Fabrice orcidid: 0000-0001-5927-4178 surname: Bonnet fullname: Bonnet, Fabrice email: fabrice.bonnet@chu-bordeaux.fr organization: University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, CHU de Bordeaux, Saint-André Hospital, Service de Médecine Interne et Maladies Infectieuses |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36348453$$D View this record in MEDLINE/PubMed https://hal.science/hal-03903474$$DView record in HAL |
| BookMark | eNp9k8tu1DAUhiNURC_wAiyQJTbtIsW3OA4LpFIVJlIpCwpby-PYM64Se7CdouENeSucTmk7FaqyiHPy_9_xOfbZL3acd7ooXiN4jBBn7yIikJESYlxCVte4RM-KPVTTqmQYVTsP1rvFfoxXEFLSEPqi2CWMUE4rslf8aV3SLlpjdQfSONdBjb2PNoIUtEyDdgkkD4LuRqVBWmow-JBkb9MaeANm7Y_SOqNVynbpOjC6u8-VTDbbI_hl03KbnbHWLWzKy8P24vLs4ttZefnxy9F7ENPYrcEq-OSV74HxAUiwWsqoQdu2IOQcfrC_M155l4Lv-2nfwcr-ZfHcyD7qV7fvg-L7p7PL01l5_vVze3pyXipGUSpJrVgnNUGEMMUwbximWmIyn1PDJTcMEWWappEYQZlXnaqwobJCpDGSGU0OinbD7by8EqtgBxnWwksrbgI-LIQMyapei67qODOGE1NhyonmHNOKoa6DVU5Wm8z6sGGtxvmgO5XbFWS_Bd3-4-xSLPy1aBiFnLIMONoAlo9ss5NzMcUgaSChNb1GWXt4myz4n6OOSQw2Kt330mk_RoFrQhmqasKz9O0j6ZUfg8ttnVSEM4hgc69ayFxsPnef96gmqDjJKlZhTifW8X9U-en0YPMhamNzfMvw5mFT7sr6d2mzAG8EKvgYgzZ3EgTFNBliMxkiT4a4mQwxVc8fmZRN-YZOt0ja_mkr2VhjzuMWOtx34wnXX6Q0I-8 |
| CitedBy_id | crossref_primary_10_1128_aac_00783_24 crossref_primary_10_1128_aac_00671_23 crossref_primary_10_1016_S2213_2600_24_00076_6 crossref_primary_10_1186_s13063_024_08133_6 crossref_primary_10_1128_spectrum_03747_23 crossref_primary_10_1093_infdis_jiaf399 crossref_primary_10_1038_s41467_024_50989_4 crossref_primary_10_1016_j_ijantimicag_2023_107048 crossref_primary_10_1155_crdi_5416948 crossref_primary_10_3389_fphar_2024_1397602 crossref_primary_10_3389_fmicb_2025_1637254 crossref_primary_10_2147_IJGM_S516998 crossref_primary_10_1007_s00203_025_04415_y crossref_primary_10_1186_s13063_023_07448_0 crossref_primary_10_1016_S2352_3018_24_00096_1 crossref_primary_10_3390_antibiotics12040702 crossref_primary_10_1056_NEJMe2310262 crossref_primary_10_3390_biom14121497 |
| Cites_doi | 10.1128/AAC.02164-18 10.1056/NEJMoa1201964 10.1056/NEJMoa040573 10.1164/rccm.201407-1264OC 10.1183/09031936.00195210 10.1038/newbio231232a0 10.1016/S1473-3099(16)30274-2 10.7554/eLife.33478 10.1128/AAC.00140-21 10.12688/wellcomeopenres.14691.1 10.1007/s40121-022-00667-z 10.1186/1471-2334-14-9 10.1128/AAC.01054-17 10.1177/0091270010366445 10.1093/cid/ciz1071 10.1038/nrneurol.2017.120 10.1056/NEJMoa1507062 10.1016/j.ijantimicag.2016.06.016 10.1128/CMR.00007-10 10.1093/cid/cix305 10.1164/rccm.200806-892OC 10.1093/jac/dks153 10.1097/INF.0b013e3181df4b9a 10.1056/NEJMe1511990 10.1128/AAC.01014-18 10.1016/S1473-3099(19)30066-0 10.1186/s40780-018-0123-1 10.1371/journal.pone.0162775 10.1016/j.jns.2010.12.015 10.1016/S1473-3099(12)70264-5 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1186/s13063-022-06772-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_d5d86ff83f52483e8824561dd054f87f PMC9640846 oai:HAL:hal-03903474v1 A733652848 36348453 10_1186_s13063_022_06772_1 |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | South Africa Sub-Saharan Africa Uganda Madagascar Ivory Coast |
| GeographicLocations_xml | – name: South Africa – name: Sub-Saharan Africa – name: Madagascar – name: Uganda – name: Ivory Coast |
| GrantInformation_xml | – fundername: EDCTP grantid: RIA2017T-2019 – fundername: ; grantid: RIA2017T-2019 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 5GY 7XB 8FK AHMBA AZQEC COVID DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c641t-37c6dae31336c6289624ea23bb4f8a8f613cf999a210acf9dc52f4a5139fa6fe3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 22 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000880339600004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1745-6215 |
| IngestDate | Mon Nov 10 04:32:07 EST 2025 Tue Nov 04 02:12:17 EST 2025 Sat Nov 29 15:10:25 EST 2025 Thu Oct 02 11:48:04 EDT 2025 Sun Oct 19 01:30:37 EDT 2025 Tue Nov 11 10:17:21 EST 2025 Tue Nov 04 18:02:46 EST 2025 Sat Mar 29 01:29:19 EDT 2025 Tue Nov 18 21:40:40 EST 2025 Sat Nov 29 06:10:09 EST 2025 Sat Sep 06 07:26:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Linezolid Aspirin Randomized controlled trial HIV, High-dose rifampicin Tuberculous meningitis HIV High-dose rifampicin |
| Language | English |
| License | 2022. The Author(s). Attribution: http://creativecommons.org/licenses/by Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c641t-37c6dae31336c6289624ea23bb4f8a8f613cf999a210acf9dc52f4a5139fa6fe3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Undefined-1 content type line 23 |
| ORCID | 0000-0001-5927-4178 |
| OpenAccessLink | https://doaj.org/article/d5d86ff83f52483e8824561dd054f87f |
| PMID | 36348453 |
| PQID | 2733860109 |
| PQPubID | 44365 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d5d86ff83f52483e8824561dd054f87f pubmedcentral_primary_oai_pubmedcentral_nih_gov_9640846 hal_primary_oai_HAL_hal_03903474v1 proquest_miscellaneous_2734615738 proquest_journals_2733860109 gale_infotracmisc_A733652848 gale_infotracacademiconefile_A733652848 pubmed_primary_36348453 crossref_primary_10_1186_s13063_022_06772_1 crossref_citationtrail_10_1186_s13063_022_06772_1 springer_journals_10_1186_s13063_022_06772_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-11-08 |
| PublicationDateYYYYMMDD | 2022-11-08 |
| PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | 6772_CR1 EM Svensson (6772_CR35) 2020; 71 MW Tenforde (6772_CR4) 2019; 19 NT Mai (6772_CR24) 2018; 7 6772_CR25 GW Rutherford (6772_CR26) 2016; 11 UK Misra (6772_CR21) 2011; 303 M Villar (6772_CR20) 2011; 38 BJ Marais (6772_CR27) 2017; 64 R Yogev (6772_CR15) 2010; 29 S Wasserman (6772_CR19) 2019; 63 K Gandelman (6772_CR17) 2011; 51 RJ Wilkinson (6772_CR2) 2017; 13 JR Vane (6772_CR23) 1971; 231 S Hashimoto (6772_CR16) 2018; 4 6772_CR33 6772_CR32 6772_CR31 T Gomes (6772_CR3) 2014; 14 V Yunivita (6772_CR28) 2016; 48 AD Heemskerk (6772_CR10) 2016; 374 S Wasserman (6772_CR29) 2021; 65 FV Cresswell (6772_CR34) 2018; 3 RE Aarnoutse (6772_CR6) 2017; 61 R Ruslami (6772_CR9) 2013; 13 MJ Boeree (6772_CR5) 2017; 17 GE Thwaites (6772_CR22) 2004; 351 PR Donald (6772_CR8) 2016; 374 MJ Boeree (6772_CR7) 2015; 191 S Dian (6772_CR11) 2018; 62 6772_CR30 R Dietze (6772_CR12) 2008; 178 M Lee (6772_CR13) 2012; 367 R Nau (6772_CR14) 2010; 23 F Pea (6772_CR18) 2012; 67 |
| References_xml | – volume: 63 start-page: e02164 year: 2019 ident: 6772_CR19 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02164-18 – volume: 367 start-page: 1508 year: 2012 ident: 6772_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa1201964 – volume: 351 start-page: 1741 year: 2004 ident: 6772_CR22 publication-title: N Engl J Med doi: 10.1056/NEJMoa040573 – volume: 191 start-page: 1058 year: 2015 ident: 6772_CR7 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201407-1264OC – volume: 38 start-page: 730 year: 2011 ident: 6772_CR20 publication-title: Eur Respir J doi: 10.1183/09031936.00195210 – volume: 231 start-page: 232 year: 1971 ident: 6772_CR23 publication-title: Nat New Biol doi: 10.1038/newbio231232a0 – ident: 6772_CR31 – volume: 17 start-page: 39 year: 2017 ident: 6772_CR5 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(16)30274-2 – ident: 6772_CR1 – volume: 7 year: 2018 ident: 6772_CR24 publication-title: eLife. doi: 10.7554/eLife.33478 – volume: 65 year: 2021 ident: 6772_CR29 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00140-21 – volume: 3 start-page: 83 year: 2018 ident: 6772_CR34 publication-title: Wellcome Open Res doi: 10.12688/wellcomeopenres.14691.1 – ident: 6772_CR33 doi: 10.1007/s40121-022-00667-z – volume: 14 start-page: 9 year: 2014 ident: 6772_CR3 publication-title: BMC Infect Dis doi: 10.1186/1471-2334-14-9 – volume: 61 start-page: e01054 year: 2017 ident: 6772_CR6 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01054-17 – volume: 51 start-page: 229 year: 2011 ident: 6772_CR17 publication-title: J Clin Pharmacol doi: 10.1177/0091270010366445 – volume: 71 start-page: 1817 year: 2020 ident: 6772_CR35 publication-title: Clin Infect Dis doi: 10.1093/cid/ciz1071 – volume: 13 start-page: 581 year: 2017 ident: 6772_CR2 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2017.120 – volume: 374 start-page: 124 year: 2016 ident: 6772_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa1507062 – volume: 48 start-page: 415 year: 2016 ident: 6772_CR28 publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2016.06.016 – volume: 23 start-page: 858 year: 2010 ident: 6772_CR14 publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00007-10 – volume: 64 start-page: 501 year: 2017 ident: 6772_CR27 publication-title: Clin Infect Dis doi: 10.1093/cid/cix305 – volume: 178 start-page: 1180 year: 2008 ident: 6772_CR12 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200806-892OC – volume: 67 start-page: 2034 year: 2012 ident: 6772_CR18 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dks153 – ident: 6772_CR32 – volume: 29 start-page: 827 year: 2010 ident: 6772_CR15 publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e3181df4b9a – ident: 6772_CR30 – volume: 374 start-page: 179 year: 2016 ident: 6772_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMe1511990 – volume: 62 start-page: e01014 year: 2018 ident: 6772_CR11 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01014-18 – volume: 19 start-page: 740 year: 2019 ident: 6772_CR4 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(19)30066-0 – volume: 4 start-page: 27 year: 2018 ident: 6772_CR16 publication-title: J Pharm Health Care Sci doi: 10.1186/s40780-018-0123-1 – volume: 11 year: 2016 ident: 6772_CR26 publication-title: PLoS One doi: 10.1371/journal.pone.0162775 – volume: 303 start-page: 22 year: 2011 ident: 6772_CR21 publication-title: J Neurol Sci doi: 10.1016/j.jns.2010.12.015 – volume: 13 start-page: 27 year: 2013 ident: 6772_CR9 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(12)70264-5 – ident: 6772_CR25 |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.4258468 |
| Snippet | Background
Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB... Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is... Background Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB... BackgroundTuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB... BACKGROUND: Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB... Abstract Background Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current... |
| SourceID | doaj pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 928 |
| SubjectTerms | Adolescent Adult Antitubercular Agents - adverse effects Aspirin Aspirin - therapeutic use Biomedicine Care and treatment Cerebrospinal fluid Clinical trials Clinical Trials, Phase III as Topic Diagnosis Dosage and administration Drug dosages Drug resistance Health Sciences HIV HIV infection HIV Infections - complications HIV Infections - diagnosis HIV Infections - drug therapy HIV, High-dose rifampicin Human immunodeficiency virus Humans Life Sciences Linezolid Medicine Medicine & Public Health Meningitis Metabolism Mortality Multicenter Studies as Topic Patient outcomes Patients Peripheral neuropathy Pharmacokinetics Randomized controlled trial Randomized Controlled Trials as Topic Rifampin Santé publique et épidémiologie South Africa - epidemiology Statistics for Life Sciences Study Protocol Testing Tuberculosis Tuberculosis, Meningeal - diagnosis Tuberculosis, Meningeal - drug therapy Tuberculous meningitis |
| SummonAdditionalLinks | – databaseName: Publicly Available Content Database dbid: PIMPY link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZYhxAv3C-BggxCAgRR09hxHF5Qhza10lpVYkzjyUqcmFbqktLLHviH_CvOcdxMYWJPvKWx49jV5-Pv5Bx_JuRNEIVawzrpa3C9fGDE3E8CHfqiADzpgCXailWfHseTiTw7S6Zue_TapVXubKI11LXaM-ZtgxHu5ZXGL-Y9WHSZRF8i-bz86eMZUhhrdQdq7JF9FN4KOmR_OhpPvzdRhVgKvts4I0VvDfbbRjFDH3XUQr_fWpyshn9jqfdmmCh5lYVeTab8K6JqF6qju_93iPfIHUdY6aBG2H1yoygfkFtjF5J_SH67JHgDXJZutlmx0ttFtZ6vaZPDTjcVXaFEbEGBbtJzy_iB_dPK0OHo1K8TwuDxtMzptmx-Os3XNcWPxe22oVl70hJcvkNV38nXQ__kYPz-E7V6uRTlJyrAOAVOTlO6nMFiTUejEYWlOa_O57-geZelv8B-4zR8RL4dHZ58GfrufAgAFu9vwDZqkacFAzdbaAGeowh5kYYsy7iRqTTAVLQBApyCW5vCVa6j0PA0AtJrUmEK9ph0yqosnhJqUOlMRDoJ05hHPJM6y2Kjg0hCAzwPPdLfAUNpJ56OZ3gslHWipFA1mBSASVkwqb5HPjTPLGvpkGtrHyDempoo-21vVKsfylkRlUe5FMZIZqKQS1aAe4QEOM-BeBsZG4-8RbQqNE7QPZ26PRYwSJT5UgMUv4yAkUiPdFs1wajoVvFrwHurM8PBscJ7MH8DxmN-AV3u7nCsnOVbq0vYeuRVU4zNYzZfWVRbW4cDk44ZvOdJPXuaVzHBuOQR80jcmletvrRLyvnM6qInggdApz3ycTcDL7v17z_-2fWjeE5uh2ghbCShSzqb1bZ4QW7qC0D46qWzMH8AzVWK4A priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgILQX7rBAQQYhAYKINHYch7cObWqlrULaqPZmJY5NK3XJ1LR74B_yrzjHdYLCAAne0vgSpz6X78THnwl5FSWx1uAnQw2hVwiImIdZpONQGJAnHbFMO7Lq2VE6ncqzs-yz3xTWtNnu7ZKks9ROraX40IC1dWuOcYisZ3EIMc-NBNlmMEY_mbX2Fzws4-32mN-267kgx9Tf2ePrc0yHvIo1r6ZM_rJu6tzR4Z3_e5G75LaHn3S0lZd75Jqp7pNbx36B_QH57lPaLSBTut4UZqU3y7pZNLTLSKfrmq6Q8NVQAI_03OF3wPK0tnQ8mYXb9C5onlcl3VTdT8_g2lD89NvvG7p15ybB5Rvk6J2eHISn-8dvP1LHfkuRTKIGiaWAsGlOL-bgeulkMqHgaMv6fPENuvc590scNyrVQ_Ll8OD00zj0pz2AmPDhGiydFmVuGATNQguIA0XMTR6zouBW5tIC7tAW4GwOQWoOV6VOYsvzBCCszYU17BHZqerK7BFqkbdMJDqL85QnvJC6KFKro0RCB7yMAzJsBUBpT4WOJ3IslQuJpFDbOVIwR8rNkRoG5F3X5mJLBPLX2vsoV11NJPF2N-rVV-VtgiqTUgprJbNJzCUzEOwgnC1LgNFWpjYgr1EqFZoaGJ7O_Y4JeEkk7VIjpLJMAF_IgAx6NcFE6F7xS5Dr3mDGoyOF90AbI8ZTfglDHrRir7wdaxSAWyYxZs8C8qIrxu4xN68y9cbV4YCLUwbPebzVku5RTDAuecICkvb0pzeWfkm1mDuW80zwCMBxQN63WvRzWH_-45_8W_WnZDdGRXTrBAOys15tzDNyU1-CxK-eO7vyA87XdAM priority: 102 providerName: Springer Nature |
| Title | Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial |
| URI | https://link.springer.com/article/10.1186/s13063-022-06772-1 https://www.ncbi.nlm.nih.gov/pubmed/36348453 https://www.proquest.com/docview/2733860109 https://www.proquest.com/docview/2734615738 https://hal.science/hal-03903474 https://pubmed.ncbi.nlm.nih.gov/PMC9640846 https://doaj.org/article/d5d86ff83f52483e8824561dd054f87f |
| Volume | 23 |
| WOSCitedRecordID | wos000880339600004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7X7 dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7RV dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: BENPR dateStart: 20000401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: PIMPY dateStart: 20000401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RSV dateStart: 20000401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbYQIiXiTuBUhmEBIhFS2PHcXhrUadWWquqG1V5shInVit1ydTLHvYP-Vec46SBMAEvvERJ7DhOfC7fiU8-E_LOC3ytwU-6GkIvFxAxdyNP-67IQJ60xyJtyapnZ-F4LOfzaPLLUl-YE1bSA5cv7iQNUimMkcwEPpcsA0SIPj9NAWsYGRq0vl4Y7YOp0gaDl2V8_4uMFCcbsNR2vtJ3kTHNdzsNN2TZ-mubfLDAlMjbePN22uRvc6fWJZ0-JEcVlqTd8hkekTtZ_pjcH1Wz5U_I9yo_3QDMpNtdkq31blVslhtap5fTbUHXyN6aUUCC9NKCcQDmtDB0MJy5Za4WXB7nKd3l9WFFx7qh-B232TY0axdBgt0PSLg7Pu-7F73Rx8_UUtlSZIYoQPwowGUa06sF-FE6HA4peM20uFzeQPNVAv0K-40a8pR8Pe1ffBm41dINMOa8swWzpUUaZwwiYKEFBHXC51nssySBQYulARChDWDTGCLOGPZSHfiGxwHgURMLk7Fn5DAv8uwFoQZJyESgIz8OecATqZMkNNoLJDTAU98hnf1IKl3xmuPyGitl4xspVDn6CkZf2dFXHYd8qq-5Klk9_lq7hwJS10RGbnsC5FRVcqr-JacOeY_ipdBuQPd0XP3-AA-JDFyqi7yUAYAF6ZBWoybou24UvwUBbXRm0D1TeA5Uy2M85NfQ5dZeflVllDYKkCqTGIBHDnlTF2PzmGiXZ8XO1uEAckMG93leint9KyYYlzxgDgkbitDoS7MkXy4sZXkkuAdI1yHHe5X52a0_v_iX_-PFvyIPfFR8OxXQIofb9S57Te7pa9CDdZschNMZbueh3co2udvrjyfTtjUocDQZjibf4Gh6PvsB1QJ2tw |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLa2DgEv3C-BAQaBAEG01HEcFwmhDTY1WltVYkzjySROzCp1SellCH4U_4N_xTlukilM7G0PvKWx45yk5_bFx58JeeoFTGuIk64G6OVCRszdjqeZKzLQJ-35HW3Jqvd74WAgDw46wxXyq1oLg2WVlU-0jjotNH4j34Aw60tED513k28u7hqFs6vVFhpLtdjNfnwHyDZ7G32A__cZYzvbe--7brmrAIjD23OwKC3SOPMBnAktAG8IxrOY-UnCjYylgfimDaRNMYChGI5SHTDD4wBSJRMLk_kw7ipZ46DsXousDaP-8HM9bxFKwaulOVJszCBC2HlS5iJTG3PbjfBndwmoY8HqIZZins5zT5dr_jVna0PhztX_7SVeI1fKpJtuLq3kOlnJ8hvkYr8sK7hJfpeF_AbycTpfJNlUL8bFbDSjdR0-nRd0ijS3GYWUmR5Z1AIIhhaGdqN9d1nUBpfHeUoXef2z5K2dUfzg3RwbhrW7RcHhC2QmHnzcdve2-i_fUMv5S5FCowA7pYAraEwnh5Bw0CiKKKQXaXE0-gnDlysNxig3upJb5NO5vMjbpJUXeXaXUINsbSLQHRaHPOCJ1EkSGu0FEgbgKXNIu1I9pUsCeNyHZKwsEJRCLdVVgboqq66q7ZBX9TWTJf3Jmb23UKPrnkhdbk8U06-q9IQqDVIpjJG-CRiXfgYQD5P4NAXwYGRoHPIc7UGhgwXxdFyuE4GHRKoytYkEngFkVdIh642e4Bh1o_kJWFRDmO5mT-E58EGez0N-DCKvV5aiSu89Uydm4pDHdTMOjxWJeVYsbB8OaCD04T53lvZZ38oXPpc88B0SNiy3IUuzJR8dWm73juAeQAKHvK5s_ESsf7_4e2c_xSNyqbvX76leNNi9Ty4z9Ed2ZmSdtObTRfaAXNDHoO3Th6U_o-TLeVv_H2y23UA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLa2Dk28cL8EChgEAgTRWttxHCSEVrZp1bZqGmPam0mdmE3qktLLEPw0_gH_inOcyxQm9rYH3tLYcU7Sc_vi48-EPO8EzBiIk74B6OVDRiz8qGOYL1PQJ9PhkXFk1Qfb4WCgDg-j3QXyq1oLg2WVlU90jjrJDX4jX4EwyxWih2jFlmURu2sbH8bffNxBCmdaq-00ChXZSn98B_g2fd9fg__6BWMb6_sfN_1yhwEQTXRnYF1GJnHKAahJIwF7SCbSmPHhUFgVKwuxzlhIoWIARjEcJSZgVsQBpE02ljblMO4iWQo5gJ4WWeqtD3b36jmMUElRLdNRcmUK0cLNmTIfWduY322EQrdjQB0XFo-wLPN8znu-dPOv-VsXFjeu_88v9Aa5VibjdLWwnptkIc1ukeWdstzgNvldFvhbyNPpbD5MJ2Y-yqfHU1rX59NZTidIf5tSSKXpiUMzgGxobulm_8Avit3g8jhL6Dyrf5Z8tlOKH8KbY8OwbhcpOHyFjMWDT-v-fm_n9TvquIApUmvkYL8U8AaN6fgIEhHa7_cppB1JfnL8E4YvVyCMUG50MXfI50t5kXdJK8uz9D6hFlncZGAiFociEENlhsPQmk6gYACRMI90KzXUpiSGx_1JRtoBRCV1oboaVFc71dVdj7yprxkXtCgX9u6hdtc9kdLcncgnX3XpIXUSJEpaq7gNmFA8BeiHyX2SAKiwKrQeeYm2odHxgngmLtePwEMihZleRWLPALIt5ZF2oyc4TNNofgbW1RBmc3Vb4znwTR0uQnEKIrcrq9GlV5_qM5PxyNO6GYfHSsUszeeujwCUEHK4z73CVutbccmFEgH3SNiw4oYszZbs-MhxvkdSdAAqeORtZe9nYv37xT-4-CmekGUweb3dH2w9JFcZuiY3YdImrdlknj4iV8wpKPvkcenaKPly2cb_Bynk5do |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intensified+tuberculosis+treatment+to+reduce+the+mortality+of+HIV-infected+and+uninfected+patients+with+tuberculosis+meningitis+%28INTENSE-TBM%29%3A+study+protocol+for+a+phase+III+randomized+controlled+trial&rft.jtitle=Trials&rft.au=Maitre%2C+Thomas&rft.au=Bonnet%2C+Maryline&rft.au=Calmy%2C+Alexandra&rft.au=Raberahona%2C+Mihaja&rft.date=2022-11-08&rft.issn=1745-6215&rft.eissn=1745-6215&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs13063-022-06772-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13063_022_06772_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |